Stem cell therapy in inflammatory bowel disease: A promising therapeutic strategy?

Table 2 Mesenchymal stem cell transplantation studies in luminal inflammatory bowel diseases

Ref.	Patient (n)	Procedence	Follow up (d, mo or wk)	SAEs	Response/remission (number of patients, time of evaluation)	Recurrence (number of patients, time of evaluation)
Onken et al[45]	10 CD (9 evaluable)	BM	28 d	No SAES	Clinical	NA
		Allogenic			3/1 (28 d)
Duijvestein et al[46]	10 CD (9 evaluable)	BM	14 wk	No SAEs	Clinical	NA
		Autologous			3/0 (6 wk)
					Endoscopic
					0/2 (6 wk)
Liang et al[47]	7 (4 CD/3UC)	BM/umbilical cord	19 mo (range 6-32)	No SAEs	Clinical	1-3
		Allogenic			7/3 (12 wk)
					Endoscopic
					3/0 (3-5 mo)
Osiris Therap-eutics[48]	Estimated 330 CD	BM	NA	NA	NA	NA
		Allogenic
Forbes et al[49]	16 CD (15 evaluable)	BM	42 d	1 SAE probably not related	Clinical	NA
		Allogenic			12/8 (42 d)
					Endoscopic
					7/0 (42 d)
Lazebnik et al[50]	39 UC 11 CD	BM	4-8 mo	NA	Clinical response	NA
		Allogenic			UC 39/39
					CD 11/11

BM: Bone marrow; SAEs: Serious adverse events; NA: Not available; CD: Crohn´s disease; UC: Ulcerative colitis.